Evidence map›Paper›PMID 41388061›Full record

ArticleScientific reports2025

Mitochondrial apoptosis and G

Sharifah Nadhira Syed Annuar, Nurul Farahana Kamaludin, Normah Awang, Kok Meng Chan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Triorganotin compounds as emerging nuclear retinoid X receptor ligands and their implications in cancer.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Sharifah Nadhira Syed AnnuarCenter for Toxicology and Health Risk Studies, Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.
Nurul Farahana KamaludinCenter for Toxicology and Health Risk Studies, Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia. nurulfarahana@ukm.edu.my.
Normah AwangCenter for Toxicology and Health Risk Studies, Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.
Kok Meng ChanProduct Stewardship and Toxicology, Petroliam Nasional Berhad, PETRONAS Twin Towers, KLCC, Kuala Lumpur, Malaysia.

Funding

Ministry of Higher Education, Malaysia,Malaysia FRGS/1/2019/STG04/UKM/03/3
6 · The paper itself

Abstract

Recent findings highlight organotin(IV) compounds as effective anticancer agents, especially for leukemia, offering a potential advancement in cancer therapy by inhibiting cell proliferation with reduced toxicity and resistance issues. Five novel di- and triphenyltin(IV) dithiocarbamate compounds (OC1-OC5) were tested against Jurkat E6.1 human lymphoblastic leukemia cells. All compounds produced potent cytotoxic effects by inducing 55% - 86% of apoptotic events at their respective IC

Indexed as

Antineoplastic AgentsApoptosisG1 Phase Cell Cycle CheckpointsMitochondriaOrganotin CompoundsPrecursor Cell Lymphoblastic Leukemia-LymphomaThiocarbamatesCell Line, TumorCell ProliferationHumansJurkat CellsMembrane Potential, MitochondrialReactive Oxygen SpeciesAntineoplastic AgentsOrganotin CompoundsReactive Oxygen SpeciesThiocarbamatestriphenyltinAnticancerApoptosisCell cycleDNA damageLeukemiaOrganotin(IV)

Identifiers

PMID41388061
PMCPMC12722729

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.